Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Research analysts at Wedbush issued their FY2022 EPS estimates for shares of Karyopharm Therapeutics in a note issued to investors on Thursday. Wedbush analyst D. Nierengarten forecasts that the company will post earnings of $2.60 per share for the year.
Several other brokerages have also commented on KPTI. Royal Bank of Canada restated a “buy” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Jefferies Group restated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Robert W. Baird restated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and an average target price of $17.33.
Shares of Karyopharm Therapeutics (KPTI) traded down $0.63 during trading hours on Monday, hitting $11.80. 147,038 shares of the company’s stock traded hands, compared to its average volume of 191,150. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%.
In other news, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $9.16, for a total value of $91,600.00. Following the completion of the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at $4,782,829.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christopher Brett Primiano sold 4,958 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total transaction of $55,777.50. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $730,969 over the last quarter. Insiders own 14.71% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC boosted its holdings in Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the second quarter worth approximately $136,000. The Manufacturers Life Insurance Company boosted its holdings in Karyopharm Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after buying an additional 5,586 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Karyopharm Therapeutics by 8.0% during the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock worth $246,000 after buying an additional 2,021 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Karyopharm Therapeutics by 33.6% during the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after buying an additional 7,099 shares in the last quarter. Institutional investors and hedge funds own 60.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Karyopharm Therapeutics Inc (KPTI) Expected to Post FY2022 Earnings of $2.60 Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/30/karyopharm-therapeutics-inc-kpti-expected-to-post-fy2022-earnings-of-2-60-per-share.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.